Brief: Kodiak Sciences Announces First Patients Enrolled In Global Phase 3 Alto Trial Of Ksi-501 In Patients With Diabetic Macular Edema
10/08/2026 23:03
BRIEF-Kodiak Sciences Announces First Patients Enrolled In Global Phase 3 Alto Trial Of Ksi-501 In Patients With Diabetic Macular Edema Aug 10 (Reuters) - Kodiak Sciences Inc. KOD.O:
KODIAK SCIENCES ANNOUNCES FIRST PATIENTS ENROLLED IN GLOBAL PHASE 3 ALTO TRIAL OF KSI-501 IN PATIENTS WITH DIABETIC MACULAR EDEMA
Source text: ID:nPnbwV9QCa
Further company coverage: KOD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kodiak Sciences
See all newsBrief: Kodiak Sciences Inc. Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing
US RESEARCH ROUNDUP-Acuity, Dell Technologies, Nike
Ocular Therapeutix tumbles on rival Kodiak's trial win, analyst calls selloff overdone
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX